INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 180 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,240,126 | +123.8% | 1,037,763 | +33.5% | 0.07% | +124.2% |
| Q2 2023 | $8,598,066 | +86951.4% | 777,402 | +5.7% | 0.03% | -21.4% |
| Q1 2023 | $9,877 | +41.3% | 735,488 | +30.1% | 0.04% | +20.0% |
| Q4 2022 | $6,991 | -99.9% | 565,185 | +5.3% | 0.04% | -10.3% |
| Q3 2022 | $7,487,000 | +4.3% | 536,764 | +3.3% | 0.04% | +2.6% |
| Q2 2022 | $7,177,000 | -9.8% | 519,722 | +6.2% | 0.04% | 0.0% |
| Q1 2022 | $7,961,000 | +25.8% | 489,352 | +26.0% | 0.04% | +26.7% |
| Q4 2021 | $6,326,000 | +26.4% | 388,350 | +15.2% | 0.03% | +15.4% |
| Q3 2021 | $5,006,000 | +40.5% | 337,141 | +88.9% | 0.03% | +30.0% |
| Q2 2021 | $3,564,000 | +89000.0% | 178,488 | +89144.0% | 0.02% | – |
| Q1 2021 | $4,000 | 0.0% | 200 | 0.0% | 0.00% | – |
| Q4 2020 | $4,000 | -50.0% | 200 | 0.0% | 0.00% | – |
| Q3 2020 | $8,000 | -20.0% | 200 | 0.0% | 0.00% | – |
| Q2 2020 | $10,000 | -23.1% | 200 | 0.0% | 0.00% | – |
| Q1 2020 | $13,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |